AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2,eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker.
